Search / Trial NCT06227481

Combined Procedures in the Treatment of Severe Acne Scars

Launched by AL-AZHAR UNIVERSITY · Jan 25, 2024

Trial Information

Current as of October 04, 2024

Not yet recruiting

Keywords

Description

This is a prospective controlled trial that will be conducted at Dermatology, venereology, and andrology Department, Al-Azhar university hospital, Assiut, in the period from March 2024 to March 2026, to assess the efficacy of combination of scar subcision with platelet rich plasma , polydioxanone mono threads or fractional carbon dioxide laser in the treatment of severe atrophic acne scars with 1:1:1 ratios and to compare between these modalities regarding safety and efficacy

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Patients with severe atrophic acne scars (as per Goodman and Baron's acne qualitative scar grading scale)
  • Exclusion Criteria:
  • * Patients with active acne lesions.
  • * Patients having a keloid formation tendency.
  • * Patients with a history of bleeding disorder or severe anemia.
  • * Pregnant or lactating women.
  • * Patients received any treatment for scars in the last 6 months.
  • * Patients using drugs causing photosensitivity or systemic retinoids in the previous 6 months (for laser group).

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0